{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:31:23Z","timestamp":1791462683493,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.canlet.2021.12.029","type":"journal-article","created":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T11:31:38Z","timestamp":1640777498000},"page":"85-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["TRIM29 regulates the SETBP1\/SET\/PP2A axis via transcription factor VEZF1 to promote progression of ovarian cancer"],"prefix":"10.1016","volume":"529","author":[{"given":"Huai-Yu","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Mei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Yue","family":"Huyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.12.029_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","article-title":"Epidemiology of epithelial ovarian cancer","volume":"41","author":"Webb","year":"2017","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.canlet.2021.12.029_bib2","doi-asserted-by":"crossref","first-page":"8213","DOI":"10.1158\/1078-0432.CCR-08-0095","article-title":"Confirmation of gene expression-based prediction of survival in non-small cell lung cancer","volume":"14","author":"Guo","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2021.12.029_bib3","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4049\/jimmunol.1900171","article-title":"Identification of the E3 ligase TRIM29 as a critical checkpoint regulator of NK cell functions","volume":"203","author":"Dou","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2021.12.029_bib4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1101\/gad.323303.118","article-title":"ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis","volume":"33","author":"Wang","year":"2019","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2021.12.029_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.tibs.2017.01.002","article-title":"TRIM family proteins: roles in autophagy, immunity, and carcinogenesis","volume":"42","author":"Hatakeyama","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.canlet.2021.12.029_bib6","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/ni.3580","article-title":"Identification of a role for TRIM29 in the control of innate immunity in the respiratory tract","volume":"17","author":"Xing","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2021.12.029_bib7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nri2413","article-title":"TRIM family proteins and their emerging roles in innate immunity","volume":"8","author":"Ozato","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2021.12.029_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lfs.2019.03.028","article-title":"MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29","volume":"224","author":"Du","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.canlet.2021.12.029_bib9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ajpath.2011.10.020","article-title":"TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer","volume":"180","author":"Liu","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2021.12.029_bib10","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.18632\/aging.202414","article-title":"Transcriptional dysregulation of TRIM29 promotes colorectal cancer carcinogenesis via pyruvate kinase-mediated glucose metabolism","volume":"13","author":"Han","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.canlet.2021.12.029_bib11","doi-asserted-by":"crossref","first-page":"13488","DOI":"10.18632\/aging.103451","article-title":"TRIM29 mediates lung squamous cell carcinoma cell metastasis by regulating autophagic degradation of E-cadherin","volume":"12","author":"Xu","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.canlet.2021.12.029_bib12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1517\/14728222.2016.1148687","article-title":"Early evidence for the role of TRIM29 in multiple cancer models","volume":"20","author":"Hatakeyama","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.canlet.2021.12.029_bib13","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1101\/gad.344184.120","article-title":"ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer","volume":"35","author":"Purohit","year":"2021","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2021.12.029_bib14","first-page":"5053","article-title":"TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185","volume":"8","author":"Qiu","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.canlet.2021.12.029_bib15","first-page":"3822","article-title":"Long noncoding RNA TP73AS1 accelerates the progression and cisplatin resistance of nonsmall cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA34a5p","volume":"22","author":"Luo","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.canlet.2021.12.029_bib16","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.4143\/crt.2015.381","article-title":"TRIM29 overexpression promotes proliferation and survival of bladder cancer cells through NF-kappaB signaling","volume":"48","author":"Tan","year":"2016","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2021.12.029_bib17","doi-asserted-by":"crossref","first-page":"118878","DOI":"10.1016\/j.bbamcr.2020.118878","article-title":"m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells","volume":"1868","author":"Hao","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.canlet.2021.12.029_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s13402-016-0312-6","article-title":"microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression","volume":"40","author":"Guo","year":"2017","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.canlet.2021.12.029_bib19","doi-asserted-by":"crossref","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-18-1495","article-title":"Loss of TRIM29 alters keratin distribution to promote cell invasion in squamous cell carcinoma","volume":"78","author":"Yanagi","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.12.029_bib20","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.acthis.2013.12.009","article-title":"TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer","volume":"116","author":"Kanno","year":"2014","journal-title":"Acta Histochem."},{"key":"10.1016\/j.canlet.2021.12.029_bib21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2009-06-227363","article-title":"SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia","volume":"115","author":"Cristobal","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2021.12.029_bib22","first-page":"388","article-title":"Regulation of PP2A by sphingolipid metabolism and signaling","volume":"4","author":"Oaks","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2021.12.029_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21238939","article-title":"The serine\/threonine protein phosphatase 2A (PP2A) regulates syk activity in human platelets","volume":"21","author":"Makhoul","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2021.12.029_bib24","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1016\/j.celrep.2020.02.012","article-title":"Challenges and reinterpretation of antibody-based research on phosphorylation of tyr(307) on PP2Ac","volume":"30","author":"Mazhar","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2021.12.029_bib25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/0008-5472.CAN-18-0717","article-title":"Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma","volume":"79","author":"Allen-Petersen","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.12.029_bib26","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108486","article-title":"Restraining CDK1-cyclin B activation: PP2A on the cUSP(7)","volume":"40","author":"Chow-Castro","year":"2021","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2021.12.029_bib27","doi-asserted-by":"crossref","DOI":"10.1007\/s12038-020-00096-5","article-title":"High-glucose-induced apoptosis, ROS production and pro-inflammatory response in cardiomyocytes is attenuated by metformin treatment via PP2A activation","volume":"45","author":"Cheng","year":"2020","journal-title":"J. Biosci."},{"key":"10.1016\/j.canlet.2021.12.029_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian cancer: an integrated review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.canlet.2021.12.029_bib29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.critrevonc.2018.12.006","article-title":"Ovarian carcinosarcoma: current developments and future perspectives","volume":"134","author":"Boussios","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2021.12.029_bib30","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.2174\/1389450118666170328114506","article-title":"Oncogenic role of SET\/I2PP2A for gynecologic cancers","volume":"18","author":"Jiang","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.canlet.2021.12.029_bib31","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3389\/fonc.2019.00462","article-title":"PP2A: a promising biomarker and therapeutic target in endometrial cancer","volume":"9","author":"Remmerie","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2021.12.029_bib32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/10409238.2016.1143913","article-title":"PP2A as a master regulator of the cell cycle","volume":"51","author":"Wlodarchak","year":"2016","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.canlet.2021.12.029_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214469","article-title":"PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH 6 hepatoblastoma cells","volume":"14","author":"Stafman","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2021.12.029_bib34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/bjc.2017.150","article-title":"MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1","volume":"117","author":"Chen","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2021.12.029_bib35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/1061186X.2016.1245307","article-title":"SET protein overexpression contributes to paclitaxel resistance in MCF-7\/S cells through PI3K\/Akt pathway","volume":"25","author":"Zhang","year":"2017","journal-title":"J. Drug Target."},{"key":"10.1016\/j.canlet.2021.12.029_bib36","first-page":"188578","article-title":"The interaction of SET and protein phosphatase 2A as target for cancer therapy","author":"Dacol","year":"1876","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2021.12.029_bib37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12929-019-0557-2","article-title":"Penfluridol triggers cytoprotective autophagy and cellular apoptosis through ROS induction and activation of the PP2A-modulated MAPK pathway in acute myeloid leukemia with different FLT3 statuses","volume":"26","author":"Wu","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.canlet.2021.12.029_bib38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ebiom.2018.12.032","article-title":"Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression","volume":"40","author":"Liu","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2021.12.029_bib39","doi-asserted-by":"crossref","first-page":"12128","DOI":"10.18632\/oncotarget.3665","article-title":"Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2021.12.029_bib40","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nrc3139","article-title":"TRIM proteins and cancer","volume":"11","author":"Hatakeyama","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2021.12.029_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015094","article-title":"Association between acquired uniparental disomy and homozygous mutations and HER2\/ER\/PR status in breast cancer","volume":"5","author":"Tuna","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2021.12.029_bib42","doi-asserted-by":"crossref","first-page":"39197","DOI":"10.1074\/jbc.M105166200","article-title":"Vezf1\/DB1 is an endothelial cell-specific transcription factor that regulates expression of the endothelin-1 promoter","volume":"276","author":"Aitsebaomo","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.12.029_bib43","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1101\/gad.287540.116","article-title":"IMPs: an RNA-binding protein family that provides a link between stem cell maintenance in normal development and cancer","volume":"30","author":"Degrauwe","year":"2016","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2021.12.029_bib44","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ncomms1678","article-title":"CPEB-mediated ZO-1 mRNA localization is required for epithelial tight-junction assembly and cell polarity","volume":"3","author":"Nagaoka","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2021.12.029_bib45","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1038\/ncomms6248","article-title":"PAR-CLIP analysis uncovers AUF1 impact on target RNA fate and genome integrity","volume":"5","author":"Yoon","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2021.12.029_bib46","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc.2017.30","article-title":"New frontiers in translational control of the cancer genome","volume":"17","author":"Truitt","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2021.12.029_bib47","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.cell.2012.04.031","article-title":"Insights into RNA biology from an atlas of mammalian mRNA-binding proteins","volume":"149","author":"Castello","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2021.12.029_bib48","doi-asserted-by":"crossref","first-page":"203","DOI":"10.15430\/JCP.2017.22.4.203","article-title":"RNA binding protein as an emerging therapeutic target for cancer prevention and treatment","volume":"22","author":"Hong","year":"2017","journal-title":"J Cancer Prev"},{"key":"10.1016\/j.canlet.2021.12.029_bib49","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41576-020-00302-y","article-title":"RNA-binding proteins in human genetic disease","volume":"22","author":"Gebauer","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.canlet.2021.12.029_bib50","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.trecan.2017.05.003","article-title":"RNA-binding proteins in cancer: old players and new actors","volume":"3","author":"Pereira","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2021.12.029_bib51","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/ijc.30199","article-title":"Modulation of tumor eIF4E by antisense inhibition: a phase I\/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer","volume":"139","author":"Duffy","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2021.12.029_bib52","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-11-0430","article-title":"A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer","volume":"17","author":"Hong","year":"2011","journal-title":"Clin. Cancer Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521006467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521006467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:01:49Z","timestamp":1759593709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521006467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":52,"alternative-id":["S0304383521006467"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.12.029","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TRIM29 regulates the SETBP1\/SET\/PP2A axis via transcription factor VEZF1 to promote progression of ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}